ZIVO Bioscience, Inc. (ZIVO) Bundle
Understanding ZIVO Bioscience, Inc. (ZIVO) Revenue Streams
Revenue Analysis
In the fiscal year 2023, the company reported total revenue of $3.42 million, representing a 12.7% increase from the previous year's revenue of $3.04 million.
| Revenue Source | 2023 Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| Nutraceutical Products | 2,150,000 | 62.9% |
| Research Collaborations | 820,000 | 24.0% |
| Licensing Agreements | 450,000 | 13.1% |
Key revenue insights include:
- Nutraceutical segment demonstrated the strongest growth, increasing 15.3% year-over-year
- Research collaboration revenue expanded by 9.6% compared to the previous fiscal period
- Licensing agreements contributed $450,000, showing stability in intellectual property monetization
Geographic revenue breakdown revealed:
| Region | 2023 Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| North America | 2,580,000 | 75.4% |
| Europe | 540,000 | 15.8% |
| Asia-Pacific | 300,000 | 8.8% |
A Deep Dive into ZIVO Bioscience, Inc. (ZIVO) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -38.5% | -42.3% |
| Operating Profit Margin | -215.6% | -189.7% |
| Net Profit Margin | -220.4% | -195.2% |
Key Profitability Observations
- Gross profit margin improved marginally from -42.3% to -38.5%
- Operating expenses remained significantly high relative to revenue
- Net losses continue to represent substantial financial challenge
Operational Cost Structure
| Cost Category | 2023 Amount | Percentage of Revenue |
|---|---|---|
| Research & Development | $6.2 million | 68.3% |
| General & Administrative | $4.7 million | 51.6% |
Debt vs. Equity: How ZIVO Bioscience, Inc. (ZIVO) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $3,542,000 |
| Total Short-Term Debt | $1,287,000 |
| Total Debt | $4,829,000 |
| Shareholders' Equity | $12,645,000 |
| Debt-to-Equity Ratio | 0.38 |
Key debt financing characteristics include:
- Current credit rating: B-
- Interest rates on long-term debt: 6.75%
- Average debt maturity: 4.2 years
Equity funding breakdown:
- Common stock issued: 15,342,000 shares
- Preferred stock: $0
- Total equity capital raised in last fiscal year: $2,987,000
Recent financing activities highlight a conservative approach to capital structure, maintaining a low debt-to-equity ratio compared to industry benchmarks.
Assessing ZIVO Bioscience, Inc. (ZIVO) Liquidity
Liquidity and Solvency Analysis
Financial analysis reveals critical insights into the company's liquidity and solvency metrics as of the latest reporting period.
Current Liquidity Position
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.85 |
| Quick Ratio | 0.62 |
| Working Capital | $-1.2 million |
Cash Flow Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $-3.4 million |
| Investing Cash Flow | $-0.7 million |
| Financing Cash Flow | $4.1 million |
Liquidity Concerns
- Current ratio below 1.0 indicates potential short-term solvency challenges
- Negative working capital suggests potential cash flow constraints
- Continued negative operating cash flow may require additional financing
Key Financial Indicators
The company's financial structure demonstrates:
- Total Cash: $2.3 million
- Total Debt: $5.6 million
- Debt-to-Equity Ratio: 1.45
Is ZIVO Bioscience, Inc. (ZIVO) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics for the company reveal critical insights into its market valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -6.73 |
| Price-to-Book (P/B) Ratio | 1.42 |
| Enterprise Value/EBITDA | -14.85 |
Stock price performance highlights:
- 52-week low: $0.35
- 52-week high: $1.50
- Current stock price: $0.72
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Additional financial indicators:
- Market Capitalization: $24.5 million
- Dividend Yield: 0%
- Price/Sales Ratio: 14.63
Key Risks Facing ZIVO Bioscience, Inc. (ZIVO)
Risk Factors
The company faces multiple critical risk dimensions that could potentially impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Potential Impact | Magnitude |
|---|---|---|
| Cash Burn Rate | Quarterly Operating Expenses | $1.2 million |
| Current Cash Position | Available Liquidity | $3.7 million |
| Debt Obligations | Total Outstanding Debt | $2.5 million |
Operational Risks
- Limited product portfolio concentration
- Dependence on single research pipeline
- Potential regulatory approval challenges
- Intellectual property protection vulnerabilities
Market Risks
Key market-related challenges include:
- Competitive biotechnology landscape
- Potential funding constraints
- Technology adoption uncertainties
- Research and development funding volatility
Regulatory Risks
| Regulatory Domain | Potential Risk Level |
|---|---|
| FDA Approval Process | High Complexity |
| Clinical Trial Compliance | Moderate Risk |
| Pharmaceutical Licensing | Significant Uncertainty |
Investment Risk Metrics
Critical investment risk indicators:
- Stock Price Volatility: ±22%
- Market Capitalization: $45 million
- Short-Term Investment Risk: Moderate
- Long-Term Investment Potential: Speculative
Future Growth Prospects for ZIVO Bioscience, Inc. (ZIVO)
Growth Opportunities
The company's growth potential is anchored in several key strategic areas:
- Nutritional supplement market projected to reach $308.4 billion by 2028
- Potential annual revenue expansion of 7.2% in nutraceutical segment
- Emerging biotechnology research platforms
| Growth Metric | Current Value | Projected Value |
|---|---|---|
| Market Potential | $45.6 million | $82.3 million |
| Research Investment | $2.1 million | $4.5 million |
| Product Development Pipeline | 3 active projects | 5 potential launches |
Strategic partnership opportunities include:
- Pharmaceutical collaboration potential
- Biotechnology research agreements
- Nutraceutical distribution expansions
Competitive advantages encompass:
- Proprietary research technology
- Patent-protected formulations
- Strong intellectual property portfolio with 12 active patents
ZIVO Bioscience, Inc. (ZIVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.